- Home
- WES vs RPRX Comparison
WES vs RPRX Comparison
Compare WES & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WES
- RPRX
- Stock Information
- Founded
- WES 2007
- RPRX 1996
- Country
- WES United States
- RPRX United States
- Employees
- WES N/A
- RPRX N/A
- Industry
- WES Natural Gas Distribution
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- WES Utilities
- RPRX Health Care
- Exchange
- WES Nasdaq
- RPRX Nasdaq
- Market Cap
- WES 14.4B
- RPRX 13.9B
- IPO Year
- WES 2008
- RPRX 2020
- Fundamental
- Price
- WES $39.73
- RPRX $35.90
- Analyst Decision
- WES Hold
- RPRX Strong Buy
- Analyst Count
- WES 5
- RPRX 4
- Target Price
- WES $40.40
- RPRX $46.75
- AVG Volume (30 Days)
- WES 910.5K
- RPRX 3.3M
- Earning Date
- WES 08-06-2025
- RPRX 08-06-2025
- Dividend Yield
- WES 9.22%
- RPRX 2.44%
- EPS Growth
- WES N/A
- RPRX 37.60
- EPS
- WES 3.34
- RPRX 2.45
- Revenue
- WES $3,634,610,000.00
- RPRX $2,263,845,000.00
- Revenue This Year
- WES $5.26
- RPRX $29.35
- Revenue Next Year
- WES $3.77
- RPRX $7.58
- P/E Ratio
- WES $11.82
- RPRX $14.71
- Revenue Growth
- WES 11.48
- RPRX 1.13
- 52 Week Low
- WES $33.60
- RPRX $24.05
- 52 Week High
- WES $43.33
- RPRX $36.89
- Technical
- Relative Strength Index (RSI)
- WES 54.36
- RPRX 56.34
- Support Level
- WES $39.26
- RPRX $35.24
- Resistance Level
- WES $41.29
- RPRX $36.89
- Average True Range (ATR)
- WES 0.76
- RPRX 0.58
- MACD
- WES 0.03
- RPRX -0.10
- Stochastic Oscillator
- WES 43.20
- RPRX 46.71
About WES Western Midstream Partners LP Common Units Representing Limited Partner Interests
Western Midstream Partners LP is a USA-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma), North-central Pennsylvania and Texas.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.